3 days ago
Cochlear Ltd (CHEOF) (FY25) Earnings Call Highlights: Navigating Growth and Challenges
Revenue Growth: 4% overall revenue growth.
Net Profit Growth: 1% net profit growth.
Cochlear Implant Revenue: 9% growth in cochlear implant revenue, with 12% growth in systems.
Developed Markets Unit Growth: 6% increase in units.
Emerging Markets Growth: Over 20% growth, with a shift towards lower-priced, lower-tier products.
Services Revenue: Declined by 10%, with expectations for growth in FY26.
Acoustics Revenue Growth: 6% growth, with Osia growing 30%.
Gross Margin: Declined by 1 percentage point to 74%.
Operating Expenses: Increased by 5%, with a focus on long-term growth and R&D.
Inventory Levels: Increased by $108 million ahead of new product launches.
Operating Cash Flow: Declined by $150 million due to increased working capital and higher income taxes paid.
CapEx: $103 million, including capacity expansion investments.
FY26 Guidance: Net profit guidance range of $435 million to $460 million, reflecting 11% to 17% growth.
Warning! GuruFocus has detected 2 Warning Sign with CHEOF.
Release Date: August 15, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
Cochlear Ltd (CHEOF) has consistently increased its R&D investment year on year, even when sales have declined, ensuring the protection of its market leadership position.
The launch of the Nexa system, a breakthrough product, is expected to drive growth with its advanced features, including the world's first smart cochlear implant.
The company is seeing strong growth in emerging markets, with over 20% growth in cochlear implant revenue.
Cochlear Ltd (CHEOF) is confident in the future growth potential due to the increasing awareness of the link between hearing loss and cognitive decline.
The company is actively working on expanding its product pipeline, including the development of a drug-eluting electrode, which could further enhance hearing preservation.
Negative Points
Sales for FY25 were below expectations, leading to a need for strategic adjustments.
The services segment experienced a 10% decline, attributed to factors such as COVID-19 impacts and economic uncertainty, particularly in the US.
The gross margin declined by 1 percentage point to 74%, partly due to a shift to lower-margin emerging markets and increased production costs at the Chengdu facility.
There is uncertainty in the services segment due to economic conditions and consumer hesitancy, especially in the US market.
The volume-based pricing in China presents a headwind for revenue and profit in FY26, impacting the overall financial outlook.
Q & A Highlights
Q: Can you elaborate on the second-half weighting of sales and the decision to maintain a net profit margin slightly below 18%? A: Sales will be significantly weighted to the second half due to the rollout of the Nexa system, which will not be fully available in all countries in the first half. We expect some surgery holds as people anticipate the new product, which will shift sales to the second half. Regarding the net profit margin, it will be above 17.5%, but we want flexibility to ensure continued investment in R&D and growth, smoothing the path back to 18% without compromising future prospects. - Diggory Howitt, CEO
Q: What response are you seeing in markets where the Nexa system has launched, and does this support your growth outlook? A: We are seeing a very positive response, with surgeons describing it as a game changer. The Nexa system's new technology and potential for long-term benefits are recognized, supporting our confidence in achieving over 10% growth in developed markets. We are also pursuing price increases across various markets, contributing to our growth outlook. - Diggory Howitt, CEO
Q: Can you clarify the expected growth in services and the factors influencing it? A: We anticipate single-digit growth in services. While there is some caution due to US consumer uncertainty, the long-term growth is driven by the expanding recipient base. Although upgrades are discretionary, they are necessary within a time window as processors wear out, ensuring eventual growth. - Diggory Howitt, CEO
Q: How does the Nexa system's multipolar stimulation compare to competitors, and what is the potential for reducing sound processor size? A: Medel does not offer multipolar stimulation, and Advanced Bionics' technology is less advanced. Our Slim Modiolar electrode's proximity to the auditory nerve enhances the benefits of focused stimulation. We foresee further reductions in sound processor size through improved power efficiency and potential advancements in electrode technology. - Diggory Howitt, CEO
Q: What impact will the volume-based pricing in China have on revenue and gross margin? A: The volume-based pricing in China will result in a revenue and profit headwind for FY26 compared to FY25. While overall volume has increased, much of the middle-tier pricing has shifted to the low tier, impacting revenue. We are cautious about quantifying the exact impact as the situation is still evolving. - Diggory Howitt, CEO
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Error in retrieving data
Sign in to access your portfolio
Error in retrieving data
Error in retrieving data
Error in retrieving data
Error in retrieving data
